|April 6, 2013|
|13:58 EDT||RHHBY||Ovarian cancer vaccine yields clinically beneficial responses|
A report today at the American Association for Cancer Research meeting in Washington demonstrated a novel two-step immunotherapy approach yielded clinically beneficial responses in patients with advanced ovarian cancer, including one patient who achieved complete remission, according to data from two phase I clinical trials presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. The treatments were given in conjunction with Roche's (RHHBY) Avastin or bevaccizumab, a drug that controls blood vessel growth. Combining bevacizumab with immunotherapy makes a powerful duo, according to Lana Kandalaft, Pharm.D., M.T.R., Ph.D., assistant professor and director of clinical development and operations at the Ovarian Cancer Research Center in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.. Currently, the vaccine trial is still open to accrual to test new combinatorial strategies. Reference Link
News For RHHBY From The Last 14 Days
|April 17, 2015|
|05:32 EDT||RHHBY||Accelerate Diagnostics appoints Pete Bantock to Chief Culture Officer|
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
|April 16, 2015|
|08:04 EDT||RHHBY||Roche granted orphan status for lymphoma treatment|
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
|April 14, 2015|
|06:30 EDT||RHHBY||Roche to seek to have cancer drug tested in 11 trials in 2015, Reuters says|
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
|April 13, 2015|
|10:01 EDT||RHHBY||Roche acquires CAPP Medical|
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
|April 8, 2015|
|15:19 EDT||RHHBY||Roche says receives European approval for Avastin plus chemotherapy|
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
|April 7, 2015|
|07:14 EDT||RHHBY||Eyeforpharma to hold a summit|
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.